Personalized drug testing for peritoneal mesothelioma treatment
Part of Cancer clinical trials.
This trial uses a test on your tumor tissue to find which chemotherapy drugs work best for you, after standard surgery and heated chemotherapy. It aims to make your treatment more effective by choosing drugs that match your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of epithelioid or biphasic malignant peritoneal mesothelioma.
- You are scheduled for cytoreductive surgery with HIPEC and follow-up therapy.
- You have enough tumor tissue from surgery for drug sensitivity testing.
- You have good overall health, with a Karnofsky score above 60, and normal blood, liver, and kidney function.
- You are willing to sign a consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether more chemotherapy after surgery can help people with a specific type of abdominal cancer (malignant peritoneal mesothelioma). It is for those who have had all visible tumor removed and have not had chemotherapy before.
This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.
This trial tests a combination of four drugs (sintilimab, bevacizumab, pemetrexed, and cisplatin) to see if they can shrink or control peritoneal mesothelioma that cannot be surgically removed. It may be an option if you have this rare cancer and are in fairly good health.
This early-phase study tests a treatment that uses a patient’s immune cells (dendritic cell therapy) combined with surgery for epithelioid mesothelioma. It aims to help the immune system better recognize and attack the cancer after chemotherapy and before/around surgery.
This study tests whether adding immunotherapy to standard chemotherapy helps people with peritoneal mesothelioma, a cancer in the lining of the abdomen. You may receive chemotherapy alone or with immunotherapy, and the goal is to improve cancer control.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Hear when a new Peritoneal Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.